CoChat

Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial

Open access
Grodin, Erica N., Bujarski, Spencer, Towns, Brandon, Burnette, Elizabeth, Nieto, Steven, Lim, Aaron, Lin, Johnny, Miotto, Karen, Gillis, Artha, Irwin, Michael R., Evans, Christopher, Ray, Lara A. · 2021 · Translational Psychiatry
Cited by 78

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Ibudilast, a neuroimmune modulator which selectively inhibits phosphodiesterases (PDE)-3, -4, -10, and -11, and macrophage migration inhibitory factor (MIF), shows promise as a novel pharmacotherapy for alcohol use disorder (AUD). However, the mechanisms of action underlying ibudilast’s effects on the human brain remain largely unknown. Thus, the current study examined the efficacy of ibudilast to improve negative mood, reduce heavy drinking, and attenuate neural reward signals in individuals with AUD. Fifty-two nontreatment-seeking individuals with AUD were randomized to receive ibudilast (n = 24) or placebo (n = 28). Participants completed a 2-week daily diary study during which they filled out daily reports of their past day drinking, mood, and craving. Participants completed an functional magnetic resonance imaging (fMRI) alcohol cue-reactivity paradigm half-way through the study. Ibudilast did not have a significant effect on negative mood (β = −0.34, p = 0.62). However, ibudilast, relative to placebo, reduced the odds of heavy drinking across time by 45% (OR = 0.55, (95% CI: 0.30, 0.98)). Ibudilast also attenuated alcohol cue-elicited activation in the ventral striatum (VS) compared to placebo (F(1,44) = 7.36, p = 0.01). Alcohol cue-elicited activation in the VS predicted subsequent drinking in the ibudilast group (F(1,44) = 6.39, p = 0.02), such that individuals who had attenuated ventral striatal activation and took ibudilast had the fewest number of drinks per drinking day in the week following the scan. These findings extend preclinical and human laboratory studies of the utility of ibudilast to treat AUD and suggest a biobehavioral mechanism through which ibudilast acts, namely, by reducing the rewarding response to alcohol cues in the brain leading to a reduction in heavy drinking.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41398-021-01478-5

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 37

  1. Ray, LA. et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abus. 45, 124–40 (2019). · DOI · Paper page
  2. Litten, RZ. et al. Medications development to treat alcohol dependence: a vision for the next decade. Addiction Biol. 17, 513–27 (2012). · DOI · Paper page
  3. Litten, RZ., Falk, DE., Ryan, ML. & Fertig, JB. Discovery, development, and adoption of medications to treat alcohol use disorder: goals for the phases of medications development. Alcohol Clin Exp Res. 40, 1368–79 (2016). · DOI · Paper page
  4. Mayfield, J. & Harris, RA. The neuroimmune basis of excessive alcohol consumption. Neuropsychopharmacology. 42, 376 (2017). · DOI · Paper page
  5. Crews, FT. et al. Neuroimmune function and the consequences of alcohol exposure. Alcohol Res. 37, 331–51 (2015).
  6. He, J. & Crews, FT. Increased MCP-1 and microglia in various regions of the human alcoholic brain. Exp Neurol. 210, 349–58 (2008). · DOI · Paper page
  7. Koob, GF. & Volkow, ND. Neurocircuitry of addiction. Neuropsychopharmacology. 35, 217–38 (2010). · DOI · Paper page
  8. Coleman LG, Crews FT. Innate immune signaling and alcohol use disorders. In: Grant KA, Lovinger DM, editors. The neuropharmacology of alcohol. Cham: Springer International Publishing; 2018. p. 369–96. · DOI
  9. Gibson, LC. et al. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur J Pharmacol 538, 39–42 (2006). · DOI
  10. Cho, Y. et al. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc Natl Acad Sci USA. 107, 11313–18 (2010). · DOI · Paper page
  11. Hertz, AL. et al. Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA. 106, 21978–83 (2009). · DOI · Paper page
  12. Gobejishvili, L., Barve, S., Joshi-Barve, S. & McClain, C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol. 295, G718–G24 (2008). · DOI · Paper page
  13. Mizuno, T. et al. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 46, 404–11 (2004). · DOI · Paper page
  14. Fox, RJ. et al. Phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 379, 846–55 (2018). · DOI · Paper page
  15. Pérez-Torres, S. et al. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and [3H] rolipram binding autoradiography: comparison with monkey and rat brain. J Chem Neuroanat. 20, 349–74 (2000). · DOI · Paper page
  16. Liu, X., Zhong, P., Vickstrom, C., Li, Y. & Liu, QS. PDE4 inhibition restores the balance between excitation and inhibition in VTA dopamine neurons disrupted by repeated in vivo cocaine exposure. Neuropsychopharmacology. 42, 1991–99 (2017). · DOI
  17. Grodin, EN. & Ray, LA. The use of functional magnetic resonance imaging to test pharmacotherapies for alcohol use disorder: a systematic review. Alcohol Clin Exp Res. 43, 2038–56 (2019). · DOI
  18. Courtney, KE., Schacht, JP., Hutchison, K., Roche, DJ. & Ray, LA. Neural substrates of cue reactivity: association with treatment outcomes and relapse. Addiction Biol. 21, 3–22 (2016). · DOI · Paper page
  19. Schacht, JP. et al. Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status. Neuropsychopharmacology. 42, 2640–53 (2017). · DOI
  20. Anton, RF., Moak, DH. & Latham, P. The obsessive compulsive drinking scale: a self‐rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res. 19, 92–99 (1995). · DOI · Paper page
  21. Adams, ZW., Schacht, JP., Randall, P. & Anton, RF. The reasons for heavy drinking questionnaire: factor structure and validity in alcohol-dependent adults involved in clinical trials. J Stud Alcohol Drugs. 77, 354–61 (2016). · DOI
  22. Heatherton, TF., Kozlowski, LT., Frecker, RC. & Fagerstrom, KO. The Fagerström test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addiction 86, 1119–27 (1991). · DOI · Paper page
  23. Bohn, MJ., Krahn, DD. & Staehler, BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 19, 600–06 (1995). · DOI · Paper page
  24. Schacht, JP. et al. Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage 56, 61–68 (2011). · DOI · Paper page
  25. Jenkinson, M., Bannister, P., Brady, M. & Smith, S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage 17, 825–41 (2002). · DOI · Paper page
  26. Andersson JL, Jenkinson M, Smith S. Non-linear registration aka spatial normalisation FMRIB Technial Report TR07JA2. FMRIB Analysis Group of the University of Oxford; 2007:1–22.
  27. Liang, K-Y. & Zeger, SL. Longitudinal data analysis using generalized linear models. Biometrika 73, 13–22 (1986). · DOI · Paper page
  28. Ziegler A. Generalized estimating equations. Springer Science & Business Media; 2011. · DOI
  29. Mann, K., Aubin, H-J., Charlet, K. & Witkiewitz, K. Can reduced drinking be a viable goal for alcohol dependent patients?. World Psychiatry 16, 325–26 (2017). · DOI
  30. Hasin, DS. et al. Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. Lancet Psychiatry 4, 469–76 (2017). · DOI · Paper page
  31. Ramirez, D., & Smith, SM. Regulation of dopamine signaling in the striatum by phosphodiesterase inhibitors: novel therapeutics to treat neurological and psychiatric disorders. Cent Nerv Syst Agents Med Chem. 14, 72–82 (2014). · DOI
  32. Bland, ST., Hutchinson, MR., Maier, SF., Watkins, LR. & Johnson, KW. The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release. Brain Behav Immun. 23, 492–97 (2009). · DOI · Paper page
  33. Airaksinen, MS. & Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 3, 383–94 (2002). · DOI · Paper page
  34. Barak, S., Carnicella, S., Yowell, QV. & Ron, D. Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. J Neurosci. 31, 9885–94 (2011). · DOI · Paper page
  35. Heberlein, A. et al. BDNF and GDNF serum levels in alcohol-dependent patients during withdrawal. Prog NeuroPsychopharmacol Biol Psychiatry 34, 1060–64 (2010). · DOI
  36. Fox, HC., Milivojevic, V., Angarita, GA., Stowe, R. & Sinha, R. Peripheral immune system suppression in early abstinent alcohol-dependent individuals: Links to stress and cue-related craving. J Psychopharmacol. 31, 883–92 (2017). · DOI
  37. Ray, LA., Bujarski, S., Yardley, MM., Roche, DJ. & Hartwell, EE. Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. Am J Drug Alcohol Abus. 43, 703–10 (2017). · DOI

Cited by

See all 78

Metadata

Authors
Grodin, E. N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M. R., Evans, C., & Ray, L. A.
Venue
Translational Psychiatry
Published
2021-06-12
Volume
11
Issue
1
Pages
355-355
ISSN
2158-3188 (ISSN-L)
OpenAlex
W3170101799
Cited by
78
References
13
FWCI
8.12
Type
journal article
Language
en
Open access
gold
Licence
Funders
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P50 DA005010-33)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. https://app.cochat.ai/papers/10.1038/s41398-021-01478-5
The paper
Grodin, E. N., Bujarski, S., Towns, B., Burnette, E., Nieto, S., Lim, A., Lin, J., Miotto, K., Gillis, A., Irwin, M. R., Evans, C., & Ray, L. A. (2021). Ibudilast, a neuroimmune modulator, reduces heavy drinking and alcohol cue-elicited neural activation: a randomized trial. Translational Psychiatry. https://doi.org/10.1038/s41398-021-01478-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.